SITAGLIPTIN

作品数：45被引量：165H指数：6
导出分析报告
相关领域：医药卫生更多>>
相关作者：陈科胡春郅慧王济纬兰俊更多>>
相关机构：北京大学沈阳药科大学丽水市人民医院北京协和医学院更多>>
相关期刊：《Journal of Pharmaceutical Analysis》《Acta Biochimica et Biophysica Sinica》《Journal of Behavioral and Brain Science》《Clinical Traditional Medicine and Pharmacology》更多>>
相关基金：国家自然科学基金中国博士后科学基金浙江省医药卫生科学研究基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
The combination of sitagliptin and bee honey extract potentiates the anti-proliferative properties of 5-fluorouracil on Caco-2 cell line without detectable inflammatory events
《Clinical Traditional Medicine and Pharmacology》2024年第4期65-75,共11页Asmaa Eisa Mohamed F.Elshal Shaden Muawia Hany Khalil 
Background:Colon cancer originates in the colon,specifically the large intestine.It carries a poor prognosis and high mortality rate due to late diagnosis and migration.Objective:Here our objective was to evaluate the...
关键词：Colon cancer Caco-2 cells 5-flourouracil SITAGLIPTIN Bee honey Raf-1 signaling Programmed cell death Cytokines 
Evaluation of Different Glycemic Control Regimens on the Prognosis of Coronary Heart Disease Combined with Type 2 Diabetes
《World Journal of Cardiovascular Diseases》2024年第10期622-630,共9页Lili Sun Hui Hui 
Aim: To explore the safety and effectiveness of combining dapagliflozin and metformin with sitagliptin in patients with coronary heart disease and type 2 diabetes whose blood sugar control is below the standard. Metho...
关键词：Coronary Heart Disease Type 2 Diabetes SITAGLIPTIN 
Effect of sitagliptin combined with Yiqi yangyin huoxue decoction on clinical efficacy and hemorheology in early diabetic nephropathy被引量：2
《World Journal of Diabetes》2023年第9期1412-1421,共10页Jun Ling Yan-Hua Yang 
BACKGROUND Early diabetic nephropathy(DN)is a complication of diabetes mellitus.It mainly affects kidney microvessels and glomerular function,and its timely and effective treatment is critical for early DN.However,the...
关键词：SITAGLIPTIN Yiqi yangyin huoxue decoction Early diabetic nephropathy Renal function Clinical effects HEMORHEOLOGY 
Anti-cancer effects of sitagliptin,vildagliptin,and exendin-4 on triple-negative breast cancer cells via mitochondrial modulation
《BIOCELL》2022年第12期2645-2657,共13页POOJA JAISWAL VERSHA TRIPATHI ANSHUL ASSAIYA DHARMENDRA KASHYAP RAHUL DUBEY ANAMIKA SINGH JANESH KUMAR HEM CHANDRA JHA RAJESH SHARMA AMIT KUMAR DIXIT HAMENDRA SINGH PARMAR 
The work was supported by the Council of Scientific and Industrial Research-Junior Research Fellowship to Ms.Pooja Jaiswal(File No.09/301(0137)/2019-EMR-I);Ms.Versha Tripathi(09/301(0138)/2019-EMR-I);We also acknowledge the India-Belarus joint project(DST/INT/BLR/P-24/2019)funded by the Department of Science and Technology;New Delhi and the research grant from Devi Ahilya University,Indore(Dev/Seedmoney2.0/2020-21/655)sanctioned to Dr.Hamendra Singh Parmar.
Triple-negative breast cancer(TNBC)cell line MDA-MB-231 is known for Warburg metabolism and defects in mitochondria.On the other hand,dipeptidyl peptidase-IV(DPP-IV)inhibitors such as sitagliptin and vildagliptin and ...
关键词：SITAGLIPTIN VILDAGLIPTIN EXENDIN-4 Apoptosis Migration VIABILITY Chemo-sensitivity Mitochondrial biogenesis 
Identification of sitagliptin binding proteins by affinity purification mass spectrometry被引量：1
《Acta Biochimica et Biophysica Sinica》2022年第10期1453-1463,共11页Xue-Ning Wang Byu-Ri Sim Hong Chen Yun-Xiao Zheng Jun-Biao Xue Lei Wang Wei-Sha Kong Kuan Zhou Shu-Juan Guo Jing-Li Hou Jiong Zhang He-Wei Jiang Sheng-Ce Tao 
supported by the grants from the National Key Research and Development Program of China(No.2016YFA0500600);the National Natural Science Foundation of China(Nos.31900112,21907065,31970130,and 31670831);Anhui Provincial Natural Science Foundation(No.2108085QH380);Grants for Scientific Research from Anhui Medical University(Nos.0601094201 and 2021xkj012).
Type 2 diabetes mellitus(T2DM)is recognized as a serious public health concern with increasing incidence.The dipeptidyl peptidase-4(DPP-4)inhibitor sitagliptin has been used for the treatment of T2DM worldwide.Althoug...
关键词：AP-MS drug-target interaction SITAGLIPTIN SILAC SPR type 2 diabetes mellitus 
Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice被引量：1
《Current Medical Science》2022年第3期513-519,共7页Shu-tong ZHOU Wen CUI Li KONG Xun YANG 
Research Foundation of Beijing Friendship Hospital(No.yyqdkt2018-8).
Objective Nonalcoholic fatty liver disease(NAFLD)is a common cause of clinical liver dysfunction and an important prepathological change of liver cirrhosis.Central obesity,type 2 diabetes mellitus,dyslipidemia,and met...
关键词：nonalcoholic fatty liver disease SITAGLIPTIN insulin resistance nonalcoholic fatty liver disease activity score 
Efficacy and Clinical Value of Combining Sitagliptin and Metformin in the Treatment of Type 2 Diabetes
《外文科技期刊数据库(文摘版)医药卫生》2022年第2期190-194,共5页DINGRui MARGULIMamuti 
Objective: to observe the effectiveness and clinical value of sigliptin + metformin in patients with type 2 diabetes mellitus (T2DM).Methods: 76 patients with T2DM treated from May 2020-May 2022 were randomly divided ...
关键词：sigliptin METFORMIN type 2 diabetes blood sugar 
Comparative Review of Drugs Used in Diabetes Mellitus—New and Old
《Journal of Diabetes Mellitus》2021年第4期115-131,共17页Furqan Ul Haq Abuzar Siraj Muhammad Atif Ameer Tanveer Hamid Mansoor Rahman Salman Khan Saad Khan Sarwat Masud 
Background: Diabetes mellitus (DM) is a syndrome of chronically elevated glucose level in the blood either due to insulin resistance, insulin deficiency or both. In addition, it may occur due to defec...
关键词：Anti-Diabetic Drugs METFORMIN SITAGLIPTIN Canagliflozin EXENATIDE PIOGLITAZONE Insulin Use and Its Efficacy GLIPIZIDE 
Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes:a randomized,double-blind,phase 3 trial(CMAS)被引量：16
《Science Bulletin》2021年第15期1581-1590,M0004,共11页Weiping Jia Jianhua Ma Heng Miao Changjiang Wang Xiaoyue Wang Quanmin Li Weiping Lu Jialin Yang Lihui Zhang Jinkui Yang Guixia Wang Xiuzhen Zhang Min Zhang Li Sun Xuefeng Yu Jianling Du Bingyin Shi Changqing Xiao Dalong Zhu Hong Liu Liyong Zhong Chun Xu Qi Xu Ganxiong Liang Ying Zhang Guangwei Li Mingyu Gu Jun Liu Guoyue Yuan Zhaoli Yan Dewen Yan Shandong Ye Fan Zhang Zhiqiang Ning Haixiang Cao Desi Pan He Yao Xianping Lu Linong Ji 
the Chinese National and Provincial Major Project for New Drug Innovation(National:2008ZX09101-002,2013ZX09401301;Provincial:2011A080501010);Shenzhen Municipal Major Project(2010-1746)。
Chiglitazar(Carfloglitazar)is a novel peroxisome proliferator-activated receptor(PPAR)pan-agonist that has shown promising effects on glycemic control and lipid regulation in patients with type 2 diabetes.In this rand...
关键词：Chiglitazar PPAR pan-agonist Type 2 diabetes Glycemic control Insulin resistance 
Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2被引量：5
《Acta Pharmacologica Sinica》2020年第11期1446-1456,共11页Meng-meng Ning Wen-ji Yang Wen-bo Guan Yi-pei Gu Ying Feng Ying Leng 
supported by a grant from the National Natural Science Foundation of China(no.81872922).
Dipeptidyl peptidase 4(DPP4),a ubiquitously expressed protease that cleaves off the N-terminal dipeptide from proline and alanineon the penultimate position,has important roles in many physiological processes.In the p...
关键词：ulcerative colitis dextran sulfate sodium dipeptidyl peptidase 4 SITAGLIPTIN glucagon-like peptide-2 GLP-2^3-33 APOPTOSIS PROLIFERATION 
全选清除导出
共5页<12345>
检索报告 对象比较 聚类工具 使用帮助 返回顶部